Partnership in Medication Management (PIMM) in Patients With Mood Disorders (PIMM)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02285608|
Recruitment Status : Unknown
Verified November 2015 by St. Joseph's Healthcare Hamilton.
Recruitment status was: Recruiting
First Posted : November 7, 2014
Last Update Posted : November 18, 2015
|Condition or disease||Intervention/treatment||Phase|
|Major Depressive Disorder Bipolar Disorder||Other: PIMM/SAM||Not Applicable|
The efficacy of anti-depressants or lithium reported in clinical trials differs from clinical experience. Various factors such as non-adherence to treatment and poor tolerability to medications have been related to treatment non-response or treatment failure in mood disorders (major depressive disorder and bipolar disorder). Premature discontinuation of treatment for mood disorders is common. The long treatments, the patients' beliefs about medications, the lack of knowledge about the medication/treatment purpose, benefits, dosage, and side effects and the relationship between patient and healthcare providers affect treatment continuation.
Investigators are proposing a sequential explanatory mixed methods study to investigate a novel program for medication training in persons with mood disorders. The ultimate purpose of the program is to improve medication adherence in these persons. The primary component of the present study will be quantitative, i.e., a randomized controlled trial with 12 months of follow-up to examine the effect of one-on-one medication training, including the use of a checklist system, on medication adherence in patients with mood disorders. The training program will include education to improve patients' knowledge regarding their medication's purpose, dosage, benefits, and side effects. The program will also include tools like a checklist or alarm clock to remind patients of when and how to take their medication. Furthermore, the program will contain an interactive listening period where healthcare professionals involved in medication dispensing will listen to patients' concerns, questions and thoughts regarding their medications. To the best of the investigators' knowledge, no research has comprehensively examined whether one-on-one medication training, as described above, may improve medication adherence in patients with mood disorders.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||166 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Health Services Research|
|Official Title:||Partnership in Medication Management (PIMM): The Effects of One-on-one Medication Training on Medication Adherence in Patients With Mood Disorders|
|Study Start Date :||January 2015|
|Estimated Primary Completion Date :||November 2016|
|Estimated Study Completion Date :||May 2017|
Partnership in Medication Management (PIMM): The nurse and the attending physician will meet with the patient and ask how s/he administers medication at home (i.e., blister pack). Initial education session: the nurse will teach the patient about his/her medications, dosage, purpose, when and how to take them. Nurse and patient will establish reminders to take his/her medication. Following the education session, patients will be required to notify the nurse when it is time to take their medications, where their medications are, dosage, purpose and side effects. Self-Administered Medication (SAM): Patients will transition to SAM once the clinical team feels that no further medication changes are required. SAM is also the model that the participants will follow after discharge.
The PIMM program will include education to improve patients' knowledge regarding their medication's purpose, dosage, benefits, and side effects. The program will also include tools like a checklist or alarm clock to remind patients of when and how to take their medication. Furthermore, the program will contain an interactive listening period where healthcare professionals involved in medication dispensing will listen to patients' concerns, questions and thoughts regarding their medications.
Other Name: Partnership in Medication Management
No Intervention: Standard Prescribing Practice(SPP)
Standard prescribing practice (SPP): medication administration will proceed as standard practice. Patients will not receive a personalized medication training. The nurse will administer the patient's medications. However, patients are encouraged to ask any questions regarding his/her medications.Patients will not be provided with any tool to help them to remember when to take their medications. The nurse will record the patient's knowledge regarding his/her medications.
- Medication adherence measured by the Medication Adherence Rating Scale (MARS). [ Time Frame: Change from baseline in the Medication Adherence Rating Scale at 2 days before discharge and 1 week, 1 month, 3 months, 6 months and 12 months post-discharge ]Medication adherence measured by the Medication Adherence Rating Scale (MARS). We will measure medication adherence at baseline and each follow up
- Time to re-hospitalization [ Time Frame: First time re-hospitalization any point during the 12-month follow-up period ]Investigators will compare the time to re-hospitalization between each study group.
- Costs of re-hospitalization [ Time Frame: First time re-hospitalization any point during the 12-month follow-up period ]Investigators will adopt a healthcare system perspective and compare the costs of first re-hospitalization between each study group. When a participant is re-hospitalized for the first time at any point during the 12-month follow-up period, investigators will conduct a chart review of the entire re-hospitalization to identify all of the direct and indirect medical resources consumed during this re-hospitalization. The chart review will cover the entire length of the re-hospitalization, even if this length exceeds the 12-month follow-up period for the participant in question.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02285608
|Contact: Carolina Oremus, MD, PhD(c)||+1(905) 522-1155 ext email@example.com|
|Contact: Margaret C McKinnon, PhD,C.Psych.||+1(905) 522-1155 ext firstname.lastname@example.org|
|Mood Disorders Program, St. Joseph's Healthcare Hamilton||Recruiting|
|Hamilton, Ontario, Canada, L8N 4K7|
|Contact: Carolina Oremus, MD,PhD(c) +1(905) 522-1155 ext 36326 email@example.com|
|Contact: Margaret C McKinnon, PhD,C.Psych. +1(905) 522-1155 ext 36645 firstname.lastname@example.org|
|Principal Investigator:||Carolina Oremus, MD, PhD(c)||McMaster University|
|Principal Investigator:||Sharon Simmons, RN,BScN,CPMHNc||St. Joseph's Healthcare Hamilton|
|Principal Investigator:||Margaret C McKinnon, PhD,C.Psych.||McMaster University|